ABCL vs CAH · rev $12.4M vs P/E 35, rev $254.25B
Abcellera Biologics Inc (ABCL) versus Cardinal Health Inc (CAH) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Cardinal Health Inc (CAH) is a medical distribution company listed on NYSE.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
Latest reported CAH revenue for 2026-06-30 was $254.25B. Net income was $1.71B. Revenue was up 14.2% from 2025-06-30 to 2026-06-30. CAH currently screens at market cap $53.00B and trailing P/E 34.6.
ABCL currently screens at market cap $1.12B. CAH currently screens at market cap $53.00B and trailing P/E 34.6.
Not investment advice. Open the ABCL and CAH stock pages for the full models.
Not investment advice.